Mydecine Innovations Group (DB:0NF0) - Cotización, noticias y análisis

Resumen de acción 0NF0

Mydecine Innovations Group Inc, empresa de biotecnología, se dedica al desarrollo y comercialización de productos de psilocibina para el tratamiento de problemas de salud mental.

Acerca de la empresa

0NF0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

No tiene una capitalización de mercado significativa (€4M)

Tiene unos ingresos inferiores a 1 millón de dólares (CA$0)

Patrimonio neto negativo

+ 2 riesgos adicionales

Competidores de Mydecine Innovations Group Inc.

Biofrontera

XTRA:B8F

€19.9m

SynBiotic

DUSE:SBX

€46.8m

Dancann Pharma

NGM:DANCAN

kr.5.0m

Apontis Pharma

XTRA:APPH

€67.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Mydecine Innovations Group
Historical stock prices
Current Share Price	US$0.012
52 Week High	US$0.42
52 Week Low	US$0.0005
Beta	3.2
1 Month Change	2,300.00%
3 Month Change	118.18%
1 Year Change	-97.33%
3 Year Change	-99.89%
5 Year Change	-99.97%
Change since IPO	-100.00%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0NF0	DE Pharmaceuticals	Mercado DE
7D	-50.0%	-4.2%	-1.7%
1Y	-97.3%	-32.1%	-0.2%

Rentabilidad vs. Industria: 0NF0 obtuvo unos resultados inferiores a los del sector German Pharmaceuticals , que el año pasado arrojó un rendimiento del -28.2%.

Rentabilidad vs. Mercado: 0NF0 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.

Volatilidad de los precios

Is 0NF0's price volatile compared to industry and market?
0NF0 volatility
0NF0 Average Weekly Movement	749.0%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: 0NF0ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 0NF0La volatilidad semanal ha pasado de 36% a 51% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc, empresa de biotecnología, se dedica al desarrollo y comercialización de productos de psilocibina para el tratamiento de problemas de salud mental. La empresa se centra principalmente en el tratamiento para dejar de fumar. Sus principales productos candidatos a fármacos son MYCO-001, MYCO-002, MYCO003 y MYCO-004.

Resumen de fundamentos de Mydecine Innovations Group Inc.

¿Cómo se comparan los beneficios e ingresos de Mydecine Innovations Group con su capitalización de mercado?
Estadísticas fundamentales de 0NF0
Capitalización bursátil	€724.62k
Beneficios(TTM)	-€12.33m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.1x

Ratio precio-beneficio (PE)

¿Está 0NF0 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0NF0
Ingresos	CA$0
Coste de los ingresos	CA$0
Beneficio bruto	CA$0
Otros gastos	CA$18.07m
Beneficios	-CA$18.07m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.29
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	-84.4%

¿Cómo se ha desempeñado 0NF0 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 0NF0

Recompensas

Análisis de riesgos

Competidores de Mydecine Innovations Group Inc.

XTRA:B8F

€19.9m

DUSE:SBX

€46.8m

NGM:DANCAN

kr.5.0m

XTRA:APPH

€67.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Recent updates

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

First half earnings released

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.